We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+49.42%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$3.93B
AUM Growth
+$917M
Cap. Flow
-$123M
Cap. Flow %
-3.14%
Top 10 Hldgs %
73.9%
Holding
131
New
35
Increased
30
Reduced
17
Closed
20

Top Buys

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$64.3M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$54.4M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$26M
4
TNGX icon
Tango Therapeutics
TNGX
+$23.5M
5
MRUS
Merus
MRUS
+$18.5M

Top Sells

Rank Stock Value
1
CAVA icon
CAVA Group
CAVA
+$295M
2
CYTK icon
Cytokinetics
CYTK
+$54.7M
3
ARGX icon
argenx
ARGX
+$44.3M
4
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$14.8M
5
FOLD
Amicus Therapeutics
FOLD
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 50.26%
2 Consumer Discretionary 47.87%
3 Technology 0.53%
4 Real Estate 0.1%
5 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELEV
51
DELISTED
Elevation Oncology
ELEV
$7.76M 0.2%
+1,513,015
New +$4.9M
OVID icon
52
Ovid Therapeutics
OVID
$427M
$7.63M 0.19%
2,500,000
– –
TRML
53
DELISTED
Tourmaline Bio
TRML
$7.2M 0.18%
314,496
+223,070
+244% +$7.87M
APLT
54
DELISTED
Applied Therapeutics
APLT
$6.86M 0.17%
+1,009,500
New +$4.53M
PDD icon
55
Pinduoduo
PDD
$126B
$6.57M 0.17%
56,500
+24,000
+74% +$3.14M
GPCR icon
56
Structure Therapeutics
GPCR
$3.37B
$6.51M 0.17%
151,780
+65,180
+75% +$2.75M
VIGL
57
DELISTED
Vigil Neuroscience
VIGL
$6.18M 0.16%
1,811,191
– –
AXSM icon
58
Axsome Therapeutics
AXSM
$11.7B
$6.13M 0.16%
+76,837
New +$6.45M
RNAC icon
59
Cartesian Therapeutics
RNAC
$218M
$5.94M 0.15%
304,555
– –
ANRO icon
60
Alto Neuroscience
ANRO
$1.04B
$5.37M 0.14%
+350,000
New +$5.48M
BDTX icon
61
Black Diamond Therapeutics
BDTX
$95.1M
$5.31M 0.14%
1,046,517
-1,000,000
-49% -$4.03M
RGNX icon
62
Regenxbio
RGNX
$616M
$5.27M 0.13%
+250,000
New +$4.45M
KLRS
63
Kalaris Therapeutics
KLRS
$80.9M
$4.98M 0.13%
286,833
– –
KYTX icon
64
Kyverna Therapeutics
KYTX
$430M
$4.97M 0.13%
+200,000
New +$5.58M
FHTX icon
65
Foghorn Therapeutics
FHTX
$278M
$4.84M 0.12%
720,720
– –
OMGA
66
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$4.83M 0.12%
1,323,530
– –
TSM icon
67
TSMC
TSM
$1.94T
$4.35M 0.11%
32,000
-35,999
-53% -$4.47M
GERN icon
68
Geron
GERN
$898M
$4.23M 0.11%
+1,281,194
New +$2.87M
STOK icon
69
Stoke Therapeutics
STOK
$1.84B
$4.05M 0.1%
+300,000
New +$1.82M
HOOK
70
DELISTED
HOOKIPA Pharma
HOOK
$4.03M 0.1%
566,641
– –
SGMT icon
71
Sagimet Biosciences
SGMT
$435M
$3.93M 0.1%
724,771
-200,000
-22% -$1.44M
PYPL icon
72
CALL
PayPal
PYPL
$50.3B
$3.89M 0.1%
58,000
– –
BEKE icon
73
KE Holdings
BEKE
$17.7B
$3.78M 0.1%
275,000
+25,000
+10% +$349K
RPTX
74
DELISTED
Repare Therapeutics
RPTX
$3.3M 0.08%
700,000
– –
MGX icon
75
Metagenomi Therapeutics
MGX
$45.6M
$3.17M 0.08%
+300,000
New +$3.45M
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2024 Portfolio in Review

As of Q1 2024, Artal Group held 131 positions worth $3.93B, up 30% from $3.01B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Artal Group withdrew a net $123M in Q1 2024, closing 20 positions and reducing 17 holdings. Its most notable exit was argenx, an estimated $44.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 50% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Artal Group opened a new position in Crinetics Pharmaceuticals worth $65.1M.

  • Artal Group's largest Q1 2024 buy was Crinetics Pharmaceuticals: 1,390,477 shares worth $65.1M.
  • Artal Group added most to Arrowhead Research in Q1 2024, an estimated $64.3M increase.
  • Artal Group's biggest Q1 2024 reduction was CAVA Group, cutting an estimated $295M.
  • Artal Group fully exited argenx in Q1 2024, selling an estimated $44.3M.
  • Artal Group's ten largest holdings make up 74% of its $3.93B portfolio in Q1 2024.
  • Artal Group opened 35 new positions and closed 20 in Q1 2024.
  • Artal Group's portfolio value rose 30% quarter-over-quarter to $3.93B.

Based on Artal Group's 13F filing for Q1 2024, filed 13 May 2024.